-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Aldeyra Therapeutics, Lowers Price Target to $9

Benzinga·04/07/2025 15:40:11
Listen to the news
BTIG analyst Thomas Shrader maintains Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and lowers the price target from $11 to $9.